Compare MNDR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNDR | JAGX |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.6M |
| IPO Year | 2023 | 2014 |
| Metric | MNDR | JAGX |
|---|---|---|
| Price | $0.91 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 358.0K | 337.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,689,000.00 |
| Revenue This Year | $608,852.40 | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.75 |
| 52 Week Low | $0.35 | $0.20 |
| 52 Week High | $5.42 | $15.48 |
| Indicator | MNDR | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 53.46 |
| Support Level | $0.79 | $0.64 |
| Resistance Level | $1.12 | $2.43 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 42.26 | 79.36 |
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services, and the Sale of medicine and medical devices. The majority of the company's revenue is derived from the Telemedicine and other services segment. Geographically, it derives revenue from Singapore.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.